Device Trial Radar · NCT05005949
STOP Persistent AF PAS
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
393
Actual
Start
Aug 19, 2021
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Conditions
- Persistent Atrial Fibrillation
Interventions
Arctic Front™ Cardiac Cryoablation Catheter SystemDevice
Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)Time frame: 36 months
- Freedom from Primary Safety EventsTime frame: 12 months
Locations
17 sites in 6 countries. Site status is shown where the registry gives one.
Hartford Hospital
Hartford, Connecticut
Cardiology Associates of Fairfield County
Stamford, Connecticut
BayCare Medical Group Cardiology
Clearwater, Florida
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.